Efficient Cleaning-In-Place Methods For Protein-Based Antibody Affinity Chromatography Resins

October 2, 2018

Chromatography resins used for the production of biopharmaceuticals need to be cleaned efficiently to ensure the safety and efficacy of the bioproduct. Impurities that are not removed can build up on the chromatography column and start to leach into the process material in subsequent cycles. Efficient cleaning of the column in each cycle will prevent fouling and minimize the risk of carrying over between cycles and batches. Column fouling can also result in a  capacity decrease over time with a subsequent decrease in the resin lifetime.

Spotlight

XenoPort, Inc.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort.

OTHER WHITEPAPERS
news image

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More
news image

Four best practices for single-use supply chain success

whitePaper | February 16, 2023

Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.

Read More
news image

The Ultimate Guide to Digitizing Pharma Manufacturing

whitePaper | September 15, 2022

The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.

Read More
news image

Utilizing Multi-parameter Epitope Binning to Understand aTherapeutic Antibody’s Mechanism of Action

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More

Spotlight

XenoPort, Inc.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort.

Events